A potential antifungal bioproduct for Microsporum canis: Bee venom

Armağan E. Ütük; Tülin Güven Gökmen; Hatice Yazgan; Funda Eşki; Nevin Turut; Şifa Karahan; İbrahim Kıvrak; Sedat Sevin; Osman Sezer

A potential antifungal bioproduct for Microsporum canis: Bee venom

2024

Natural treatment options for Microsporum canis dermatophytosis are being explored because of resistance to several antifungal medications. In this study, the potential antifungal effect of bee venom (BV), a natural antimicrobial agent, on M. canis was investigated. The antifungal effects of BV, fluconazole, itraconazole, amphotericin B and terbinafine were evaluated by the macrodilution method at various concentrations by modifying the microdilution method recommended by the European Committee on Antimicrobial Susceptibility Testing. All isolates were observed to be susceptible to terbinafine and fully resistant to fluconazole and amphotericin B. Minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) values of M. canis isolate 2 (Mc2) were determined as 8 µg/mL for itraconazole. The MIC and MFC values of BV were found to be 320 µg/mL for the Mc2 isolate and 640 µg/mL for the Mc6 isolate. The results showed that the isolates obtained from clinical samples in this study were highly resistant to all antifungal agents, except terbinafine. The increase in resistance indicates that antifungal drugs will become insufficient and ineffective over time and natural products such as BV should be evaluated as alternatives. Contribution: Although there are many drugs for the treatment of M. canis, the increase in resistance to antifungal agents reveals the need for the identification and development of new natural agents. Bee venom, which has been shown to have a safe and weak allergenic effect in various studies, can be tested for usability as a local antifungal drug when supported by in vivo studies.

Afficher plus [+]